# Nkarta

NKX101 (NKG2D CAR-NK) — phase I in acute myeloid leukaemia.

Source: https://en.bioecon.ru/companies/nkarta/
Updated: 2026-06-24

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $250.9 million in cash, cash equivalents, and investments as of December 31, 2023; over $381 million in cash as of December 31, 2024 | https://endpoints.news/nkarta-trims-headcount-as-it-sets-sights-on-autoimmune-cell-therapy/, https://ir.nkartatx.com/node/9021/pdf, https://www.biopharmadive.com/news/nkarta-layoffs-restructuring-autoimmune-cell-therapy/743693/ |
| Production site | Two cGMP facilities in South San Francisco, California | https://ir.nkartatx.com/news-releases/news-release-details/nkarta-establishes-new-combined-nk-cell-therapy-manufacturing, https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/nktx-20251231.htm |
| Regulatory approval | Orphan Drug Designation for NKX101 for the treatment of acute myeloid leukemia (AML) granted by the FDA in December 2021 | https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/nktx-ex99_1.htm |
| Headcount | 108 employees as of March 31, 2026 | https://stockanalysis.com/stocks/nktx/employees/ |
| Revenue | $0.000B as of 2026 | https://www.macrotrends.net/stocks/charts/NKTX/nkarta/number-of-employees |

Independent sources: biopharmadive.com, endpoints.news, macrotrends.net, sec.gov, stockanalysis.com

## Technologies

- [NK-cell & CAR-NK therapy](https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/)